Ten simple rules for building a successful science start-up

07.04.2022

Plos Computational Biology

A peer-reviewed publication with a mix of thoughts and experiences from our Founding Partner Dr. Tobias Reichmuth and our Scientific Advisor Prof. Dr. Collin Y. Ewald.

New innovation longevity research prize launched

01.03.2022

longevity.technology

The most innovative longevity research could bag 50k CHF thanks to Maximon, which is launching its first Prize for Translational Research in Longevity.

Longevity: Der HealthTech Trend, auf den der Company Builder Maximon setzt

01.02.2022

Trending Topics

Wer ein neues Schlagwort in der HealthTech-Branche sucht, wird bei Longevity fündig. Kleine wie große Unternehmen suchen verstärkt nach Medikamenten, Therapien und digitalen Mitteln, um die Langlebigkeit von Menschen in überalterten Gesellschaften wie Europa oder Japan zu verbessern.
Mit Maximon, gegründet von den Schweizer Unternehmern Tobias Reichmuth und Marc Bernegger, gibt es einen neuen Company Builder, der auf Longevity-Startups setzt.

European investors have a new obsession: longevity

21.12.2021

Sifted

Imagine a world where the average life expectancy is well over 100 years (and doesn’t involve spending 30 years in a care home). Imagine a world where — thanks to scientific findings made over the last five years — there’s a cure for ageing.

Sophie Chabloz darüber, welche Stoffe das Altern bremsen können

11.10.2021

Handelszeitung

Die Gesundheitswissenschafterin Sophie Chabloz über Nahrungsergänzungsmittel, die verjüngen können. Sie erzählt, was sie selber nimmt und wie es wirkt.

Maximon launches 100 million Longevity Co-Investment Fund

07.10.2021

longevity.technology

The Longevity Co-Investment Fund finances longevity-focussed start-up companies launched by company-builder Maximon.

First companies benefit from Maximon's Longevity Co-Investment Fund

07.10.2021

startupticker.ch

The newly launched CHF 100 million Fund finances longevity-focussed start-ups founded by Swiss company builder Maximon. The Fund’s first investments include Zug based companies AVEA and Biolytica.

Tobias Reichmuth, Mitgründer Maximon, im Interview

10.09.2021

moneycab

Herr Reichmuth, Longevity, oder Langlebigkeit, tönt ein wenig nach der Suche des heiligen Grals, dem Wunsch, ewig jung zu sein. Wollen Sie das ewige Leben ermöglichen?

The Rising Importance of Crypto in Aging Research

23.07.2021

lifespan.io

The cryptocurrency world is colliding with aging research and life extension and could change how research gets funded.

Maximon gründet den weltweit ersten Longevity Company Builder

11.03.2021

moneycab.com

Zug – Maximon ist ein neuer Company Builder mit Sitz in der Schweiz, der das Ziel verfolgt, den “Health-Span”, also die Zeitspanne ohne Altersleiden und Krankheiten, zu verlängern und Menschen eine fitte, gesunde und glückliche Langlebigkeit zu ermöglichen.

Can finance give Old Father Time a run for his money?

13.03.2021

swissinfo.ch

It looks like longevity is in it for the long run in Switzerland. Financiers are serious about funding the science of longer and healthier lives. The Swiss “Longevity Valley” dream also has political backing.

Serial Entrepreneurs gründen Company Builder mit Fokus auf Langlebigkei

09.03.2021

startupticker.ch

Maximon soll in den kommenden Jahren systematisch Startups hervorbringen, deren Produkte die Zeitspanne ohne Altersleiden und Krankheiten verlängern. Das vierköpfige Gründungsteam hat bereits Millionen investiert und arbeitet an ersten Projekten.

Maximon builds new longevity companies from scratch

08.03.2021

lifeforever.club

“The real difference is that we really build the companies from scratch,” - Tobias Reichmuth, co-founder of Maximon.

Swiss longevity company builder launches

07.03.2021

longevity.technology

Swiss-based Maximon already moving forward with companies focused on precision supplements and personalised longevity advice.

The economic value of targeting aging

05.07.2021

Nature Aging

A recent paper written by economist Martin Ellison of Oxford University. biologist David Sinclair of Harvard Medical School, and economist Andrew Scott from London Business School, calculates that an intervention that successfully slows down biological aging—lowering mortality and frailty at each age, such that U.S. life expectancy would increase by just one year—is estimated to be worth $37 trillion in net present value terms. That’s the equivalent of around $700 billion annually, more than 3 percent of the country’s entire GDP.